卡马替尼致假性急性肾损伤:一例病例报告
一例84岁MET外显子14跳跃突变肺癌合并CKD3期患者,卡马替尼治疗中血肌酐从1.6mg/dL升至2.44mg/dL,停药后改善、再用药再升。用胱抑素C和碘海醇清除率评估GFR无明显变化,提示为假性AKI。
要点
- MET抑制剂可致无症状血肌酐升高,易误判为AKI。
- 胱抑素C和碘海醇清除率可鉴别假性AKI。
- 避免不必要的肾活检和过早停用抗癌药。
核心结论
- 卡马替尼可导致无症状的血肌酐升高,应通过非肌酐方法评估GFR以区别于真性AKI。
研究设计与样本
- 单例病例报告:84岁男性非小细胞腺癌合并小细胞肺癌、MET外显子14跳跃突变、CKD3期。
主要发现
- 基线Scr 1.6mg/dL,卡马替尼治疗中升至2.44mg/dL(eGFR 24mL/min/1.73m2)。
- 停药后Scr降至1.84mg/dL,再用药升至2.22mg/dL。
- 胱抑素C和肾碘海醇清除率显示GFR无明显变化,尿检和尿蛋白肌酐比无异常。
- 减量继续用药后第三次Scr升高,随后自发回到基线。
临床怎么用
- 对MET抑制剂治疗中出现Scr升高的患者,用胱抑素C或清除率方法评估GFR以鉴别假性AKI。
- 确认假性AKI后可避免肾活检并继续抗癌治疗(必要时减量)。
局限性
- 单例病例报告,结论外推受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We present a case of pseudo-acute kidney injury (AKI) following capmatinib therapy in an 84-year-old man with combined non-small cell (adenocarcinoma) and small cell lung cancer with MET exon 14-skipping mutation. His past medical history was significant for chronic kidney disease stage 3 with a baseline serum creatinine (Scr) of 1.6mg/dL rising to 2.44mg/dL (estimated glomerular filtration rate [GFR] 24mL/min/1.73m2) while on capmatinib. Scr improved to 1.84mg/dL with the cessation of capmatinib but rose again to 2.22mg/dL upon resumption of therapy. Further investigation with cystatin C and renal iothalamate clearance showed that despite fluctuation in Scr levels, there was not much variation in GFR calculated using these methods. Urinalysis and urinary protein-creatinine ratio were unremarkable. Treatment with capmatinib was continued at reduced dose and a third instance of rise in Scr was observed, followed by a spontaneous return to baseline. Thus, MET inhibitor therapy can result in an asymptomatic rise in Scr, and it must be distinguished from AKI with more accurate non-creatinine-based methods to evaluate GFR. This could spare such patients from invasive diagnostic tests, such as a kidney biopsy, and premature cessation of prognostically important cancer therapies.
引用
- Mohan A, Herrmann SM. Capmatinib-Induced Pseudo-Acute Kidney Injury: A Case Report. Am J Kidney Dis. 2021. PMID: 34118303. doi:10.1053/j.ajkd.2021.04.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。